Page 96 - 南京医科大学自然版
P. 96

第46卷第7期
               ·1042 ·                           南 京    医 科 大 学 学         报                        2026年7月


             (续表2)
                                                            PRMT1 expression[n(%)]
                Clinicopathological feature  Cases(n)                                      χ 2          P
                                                            Low            High
                  ER status                                                               4.257        0.039
                   Negative                  55          15(27.27)       40(72.73)
                   Positive                  21          11(52.38)       10(47.62)
                  PR status                                                               0.348        0.555
                   Negative                  42          13(30.95)       29(69.05)
                   Positive                  32          12(37.50)       20(62.50)
                  HER2 status                                                             0.005        0.942
                   Negative                  40          14(35.00)       26(65.00)
                   Positive                  38          13(34.21)       25(65.79)
                  Ki67 status                                                             0.624        0.430
                   Negative                  59          21(35.59)       38(64.41)
                   Positive                  15          07(46.67)       08(53.33)
                  Clinical subtype                                                        4.091        0.252
                   Luminal A                 9           04(44.44)       05(55.56)
                   Luminal B                 33          07(21.21)       26(78.79)
                   HER2⁃positive             26          11(42.31)       15(57.69)
                   Triple⁃negative           9           04(44.44)       05(55.56)

              2.4  PRMT1表达与乳腺癌患者预后的关系                           结果显示,PRMT1高表达乳腺癌患者的RFS显著短
                  利用OSdream在线工具对GEO数据库中的6个                      于低表达患者(图 4A~C)。同时,与 PRMT1 低表达
              独 立 数 据 集(GSE42568、GSE17705、GSE9195、              乳腺癌患者相比,PRMT1高表达患者的MFS显著缩
              GSE24450、GSE12276 及 GSE1456)进行生存分析。               短(图4D~F)。


              A                                B                   Low expression  C
                1.00              Low expression  1.00                            1.00
                                  High expression                  High expression
                0.75                             0.75                             0.75
               RFS rate  0.50                   RFS rate  0.50                   RFS rate  0.50    Low expression
                                                                                                   High expression
                0.25                             0.25                             0.25
                    P=0.037                          P=0.019                          P=0.017
                    HR=1.866                         HR=1.777                         HR=6.310
                    (95%CI:1.039-3.349)             (95%CI:1.101-2.869)              (95%CI:1.398-28.485)
                  0                                0                                0
                     0    25    50    75   100       0     25    50   75   100        0    25    50    75   100
                            Time(months)                    Time(months)                     Time(months)
              D  1.00                          E  1.00                         F  1.00
                                                                  Low expression
                                                                  High expression
                0.75                             0.75                             0.75
               MFS rate  0.50     Low expression  MFS rate  0.50                 MFS rate  0.50    Low expression
                                  High expression
                                                                                                   High expression
                0.25                             0.25                             0.25
                    P=0.028                          P=0.047                          P=0.028
                    HR=2.160                         HR=1.353                         HR=2.076
                    (95%CI:1.085-4.301)             (95%CI:1.004-1.822)              (95%CI:1.083-3.978)
                  0                                0                                0
                     0    25    50    75   100       0     25    50   75   100        0    25    50    75   100
                            Time(months)                    Time(months)                     Time(months)
                 A-C:Analysis of the relationship between PRMT1 expression and recurrence⁃free survival(RFS)in breast cancer patients using the OSdream
              website in datasets GSE42568(A),GSE9195(B),and GSE17705(C)from the GEO database. D-F:Analysis of the relationship between PRMT1
              expression and metastasis⁃free survival(MFS)in breast cancer patients using the OSdream website in datasets GSE24450(D),GSE12276(E),and
              GSE1456(F)from the GEO database.
                                           图4   PRMT1高表达与乳腺癌患者不良预后相关
                         Figure 4  High expression of PRMT1 is associated with poor prognosis in breast cancer patients
   91   92   93   94   95   96   97   98   99   100   101